<code id='B1A8FA9486'></code><style id='B1A8FA9486'></style>
    • <acronym id='B1A8FA9486'></acronym>
      <center id='B1A8FA9486'><center id='B1A8FA9486'><tfoot id='B1A8FA9486'></tfoot></center><abbr id='B1A8FA9486'><dir id='B1A8FA9486'><tfoot id='B1A8FA9486'></tfoot><noframes id='B1A8FA9486'>

    • <optgroup id='B1A8FA9486'><strike id='B1A8FA9486'><sup id='B1A8FA9486'></sup></strike><code id='B1A8FA9486'></code></optgroup>
        1. <b id='B1A8FA9486'><label id='B1A8FA9486'><select id='B1A8FA9486'><dt id='B1A8FA9486'><span id='B1A8FA9486'></span></dt></select></label></b><u id='B1A8FA9486'></u>
          <i id='B1A8FA9486'><strike id='B1A8FA9486'><tt id='B1A8FA9486'><pre id='B1A8FA9486'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          fashion

          author:hotspot    - browse:378
          Dozens of sickle cells in a whirlpool — coverage from STAT
          Adobe

          Nearly a decade ago, consultants delivered to Rodger Novak a kind of Sears catalog of human malady: 200 pages, listing dozens of different diseases, each annotated with — from a business standpoint — their best and worst attributes. 

          The document was supposed to help Novak, then the chief executive of CRISPR Therapeutics, navigate a pressing quandary. His company, along with two others, were founded to commercialize the new revolutionary gene-editing tool CRISPR-Cas9, which promised to cure numerous genetic diseases. But which should they target first? What was the best proof-of-concept?

          advertisement

          “We looked at anything and everything,” said Novak, who stepped down as CEO in 2017 but remained on the board until this year. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus